This is a routine proxy filing with no immediate trading catalyst. Monitor the May 28 shareholder vote for approval of the Exact Sciences warrants and share option plan, which would create future dilution but also signal continued strategic partnership with Exact Sciences. The authorized capital renewal gives the board flexibility for future equity raises — watch for any subsequent capital markets activity.
Price Chart
Executive Summary
MDxHealth filed a 6-K furnishing proxy materials for its May 28, 2026 ordinary and extraordinary general shareholders' meetings. Key proposals include issuing 3,000,000 warrants to Exact Sciences at $5.265/share, a 3,000,000 share option plan for personnel, and renewing authorized capital up to 100% of current capital for five years. This is a routine administrative filing with no financial results or material operational updates.
Key Facts
- Ordinary and extraordinary general shareholders' meetings scheduled for May 28, 2026.
- Proposal to issue 3,000,000 warrants to Exact Sciences (Genomic Health, Inc.) at an exercise price of USD 5.265 per share, expiring January 8, 2031.
- Proposal to issue 3,000,000 share options under a new 2026 Share Option Plan for personnel, with a 10-year term.
- Proposal to renew authorized capital authorization for the board to increase share capital by up to 100% of current capital for five years.
- Board report notes prior use of authorized capital: EUR 831,123.31 (Oct 2023), EUR 35,858,359.48 (Sep 2024), EUR 4,084,379.73 (Oct 2024), EUR 3,866,208.91 (Oct 2025).
- Annual remuneration of statutory auditor BDO set at EUR 275,000 for the new three-year term.
- Re-appointment of directors Michael K. McGarrity (3-year term), Ahok BV/Koen Hoffman (2-year term), and Dr. Sanford Jay Siegel (2-year term).
Financial Impact
No financial results reported. Potential future dilution from up to 6,000,000 new shares (3M warrants + 3M options) if exercised, plus up to 100% capital increase authorization. Exact Sciences warrants have a $5.265 exercise price; current market price not disclosed in filing.
Risk Factors
- Potential dilution from up to 6 million new shares if warrants and options are fully exercised.
- Authorized capital renewal allows board to issue up to 100% of current capital without shareholder vote, increasing future dilution risk.
- No financial performance data provided in this filing — fundamental business trends remain opaque.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-049539 |
| Document: ea028805601ex99-1.htm | 0001213900-26-049539 |
| Document: ea028805601ex99-4.htm | 0001213900-26-049539 |
| Document: ea028805601ex99-5.htm | 0001213900-26-049539 |
| Document: ea028805601ex99-6.htm | 0001213900-26-049539 |
| Document: ea028805601ex99-2.htm | 0001213900-26-049539 |
| Document: ea0288056-6k_mdxhealth.htm | 0001213900-26-049539 |
| Document: 0001213900-26-049539-index-headers.html | 0001213900-26-049539 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 11d ago | 6-K | $0.2070 $0.1830 | ▲ +11.59% | ▲ +11.69% | $0.1970 (+4.83%) |
Oct 15, 2026 12d ago | SC 13D/A | $0.2066 $0.1833 | ▲ +11.28% | ▲ +10.85% | $0.1970 (+4.65%) |
Oct 15, 2026 12d ago | Press Release | $0.2066 $0.1833 | ▲ +11.28% | ▲ +10.85% | $0.1970 (+4.65%) |
Sep 17, 2026 5w ago | 144 | $0.6300 $0.5650 | ▲ +10.32% | ▲ +11.59% | $0.1970 (+68.73%) |
Sep 3, 2026 7w ago | 6-K | $0.7484 $0.7072 | ▲ +5.51% | ▲ +4.30% | $0.1970 (+73.68%) |
Aug 13, 2026 10w ago | 6-K | $0.8080 $0.7431 | ▲ +8.03% | ▲ +6.66% | $0.1970 (+75.62%) |
Aug 13, 2026 10w ago | Press Release | $0.8080 $0.7431 | ▼ −8.03% | ▼ −6.66% | $0.1970 (−75.62%) |
Jul 24, 2026 13w ago | 6-K | $0.4180 $0.4180 | · 0.00% | ▲ +1.07% | $0.1970 (+52.87%) |
Jul 2, 2026 16w ago | Press Release | $0.4765 $0.4899 | ▼ −2.81% | ▼ −1.88% | $0.1970 (+58.66%) |
Apr 29, 2026 25w ago | 6-K | $2.04 $2.01 | ▼ −1.47% | ▼ −3.20% | $0.1970 (−90.34%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers